Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 677-683

  Wu, Alan H B ^a   Lorizio, Wendy ^b   Tchu, Simone ^a   Lynch, Kara ^a   Gerona, Roy ^a   Ji, Wuyang ^a   Ruan, Weiming ^a   Ruddy, Kathryn J ^c   Desantis, Stephen D ^c   Burstein, Harold J ^c   Ziv, Elad ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Activity score; Breast cancer; CYP2D6; Endoxifen; Genotype; Tamoxifen

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN; VENLAFAXINE;

ADULT; AGE; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CONTROLLED STUDY; CYP2D6 GENE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; GENOTYPE; HOT FLUSH; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; RACE DIFFERENCE; VAGINAL DRYNESS;

ADULT; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; TAMOXIFEN;

EID: 84863728228     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1963-2     Document Type: Article

References (23)

1. Brauch H, Murdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770-1782
2. Goetz MP, Know SK, Suman VJ et al (2006) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121
3. Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphism and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
4. Lash TL, Lien EA, Sorensen HT, Hamilto-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet 10:825-833
5. Rae JM, Drury S, Hayes DF et al. (2010) Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial [abstract S1-7]. Abstract presented at: 33rd Annual San Antonio breast cancer symposium; San Antonio, TX, December 8-12, 2010. http://www.abstracts2 view.com/sabcs10/view.php?nu=SABCS10L-1093 Accessed 3 March 2011
6. Leyland-Jones B, Regan MM, Bouzk M et al. (2010) Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial [abstract S1-8]. Abstract presented at: 33rd Annual San Antonio breast cancer symposium; San Antonio, TX, December 8-12, 2010 http://www.abstracts2view.com/sabcs 10/view.php?nu=SABCS10L-556 Accessed 3 March 2011
7. International Warfarin Pharmacogenetics Consortium (2009) Improved warfarin dosing with a global pharmacogenetic algorithm. N Engl J Med 360:753-764
8. Borges S, Desta Z, Jin Y et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450-458
9. Madlensky L, Natarajan L, Tchu S et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype and breast cancer outcomes. Clin Pharmacol Ther 89:718-725
10. Lorizio W, Beattie M, Tchu S et al (2011) Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med 3:64
11. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74
12. Tchu S, Lynch K, Wu AHB (2011) Therapeutic drug monitoring of tamoxifen using LC-MS/MS. In: Langman LJ, Snozek CLH (eds) Methods in molecular biology-LC-MS in drug analysis. Springer, New York (in press)
13. Wu AHB, Gerona R, Armenian P et al (2011) Comprehensive drug testing using liquid chromatography-time-of-flight mass spectrometry for clinical toxicology. Clin Toxicol (submitted)
14. Package insert (2007) AmpliChip CYP450 test. Roche Molecular Systems, Branchburg, NJ
15. Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74
16. Wu AHB, Babic N, Yeo JT (2009) Implementation of phar-macogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Personalized Med 6:315-327
17. Irvin WJ, Walko CM, Weck KE et al (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29:3232-3239
18. Rae JM, Sikora MJ, Henry NL et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258-264
19. Lubitz SA, Scott SA, Rothlauf EB et al (2010) Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J Thromb Haemost 8:1018-1026
20. Brown RR, Bain R, Jordan VC (1983) Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. J Chromatogr 272:351-358
21. Gurley BJ, Swain A, Hubbard MA et al (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effect of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 52:755-763
22. Murdter TE, Schroth W, Bacchus-Gerybadze L et al (2011) The German Tamoxifen and AI Clinicians Group. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of Phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
23. Jaremko M, Kasai Y, Barginear MF et al (2010) Tamoxifen metabolite isomer separation and quantification by liquid chro-matography-tandem mass spectrometry. Anal Chem 92:10186-10193